Wikiwand AI

Alnodesertib

Investigational drug From Wikipedia, the free encyclopedia

Alnodesertib is an investigational new drug that is being developed by Artios Pharma for the treatment of solid tumours.[1][2] It is an ataxia telangiectasia and Rad3 related (ATR) protein inhibitor.[1][3][4]

Other namesGTPL13731; BDBM570448; ART-0380; IACS-030380
CAS Number
PubChem CID
IUPHAR/BPS
Quick facts Clinical data, Other names ...
Alnodesertib
Clinical data
Other namesGTPL13731; BDBM570448; ART-0380; IACS-030380
Identifiers
  • 4-[4-[(cyclopropyl-methyl-oxo-λ6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC18H24N6O2S
Molar mass388.49 g·mol−1
3D model (JSmol)
  • C[C@@H]1COCCN1C2=NC(=NC(=C2)N=[S@](=O)(C)C3CC3)C4=CC(=NC=C4)N
  • InChI=InChI=1S/C18H24N6O2S/c1-12-11-26-8-7-24(12)17-10-16(23-27(2,25)14-3-4-14)21-18(22-17)13-5-6-20-15(19)9-13/h5-6,9-10,12,14H,3-4,7-8,11H2,1-2H3,(H2,19,20)/t12-,27+/m1/s1
  • Key:JHPDHYAMSPMBIF-MUDIAHQHSA-N
Close

Clinical trials

Alnodesertib is currently in clinical trials for solid tumors.[5] Another study was terminated "not for reasons affecting the benefit-risk balance".[6]

References

Related Articles

Timelines

Top Qs

Fact Checks